Free Trial

ADMA Biologics (NASDAQ:ADMA) Reaches New 1-Year High at $11.11

ADMA Biologics logo with Medical background

ADMA Biologics, Inc. (NASDAQ:ADMA - Get Free Report)'s share price reached a new 52-week high during trading on Monday . The stock traded as high as $11.11 and last traded at $11.11, with a volume of 9856 shares. The stock had previously closed at $11.00.

Analyst Ratings Changes

Several research firms recently commented on ADMA. HC Wainwright boosted their target price on ADMA Biologics from $7.50 to $10.00 and gave the stock a "buy" rating in a research report on Friday, May 10th. Mizuho upped their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Thursday. Cantor Fitzgerald upped their price objective on ADMA Biologics from $8.00 to $10.00 and gave the stock an "overweight" rating in a report on Friday, May 10th. Finally, Raymond James upped their price objective on ADMA Biologics from $8.00 to $10.00 and gave the stock a "strong-buy" rating in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $11.00.

Check Out Our Latest Research Report on ADMA

ADMA Biologics Price Performance

The stock has a market capitalization of $2.55 billion, a PE ratio of -550.50 and a beta of 0.48. The business has a fifty day moving average price of $8.72 and a 200-day moving average price of $6.52. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91.


ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.05 by $0.03. The company had revenue of $81.90 million during the quarter, compared to analysts' expectations of $77.28 million. ADMA Biologics had a positive return on equity of 17.24% and a negative net margin of 1.29%. ADMA Biologics's quarterly revenue was up 43.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.03) EPS. Research analysts expect that ADMA Biologics, Inc. will post 0.35 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In related news, CEO Adam S. Grossman sold 100,000 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $10.72, for a total transaction of $1,072,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,081,475 shares in the company, valued at approximately $22,313,412. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 3.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ADMA. Swiss National Bank raised its position in ADMA Biologics by 1.0% during the 3rd quarter. Swiss National Bank now owns 439,800 shares of the biotechnology company's stock valued at $1,574,000 after purchasing an additional 4,300 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in ADMA Biologics by 182.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,609,346 shares of the biotechnology company's stock valued at $5,761,000 after purchasing an additional 1,039,893 shares during the last quarter. HighTower Advisors LLC raised its position in ADMA Biologics by 111.1% during the 3rd quarter. HighTower Advisors LLC now owns 72,517 shares of the biotechnology company's stock valued at $258,000 after purchasing an additional 38,160 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in ADMA Biologics during the 3rd quarter valued at approximately $58,000. Finally, Invesco Ltd. raised its position in ADMA Biologics by 8.5% during the 3rd quarter. Invesco Ltd. now owns 5,417,166 shares of the biotechnology company's stock valued at $19,393,000 after purchasing an additional 426,446 shares during the last quarter. Institutional investors own 75.68% of the company's stock.

About ADMA Biologics

(Get Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Featured Stories

→ Kiss of death from Joe Biden (From Porter & Company) (Ad)

Should you invest $1,000 in ADMA Biologics right now?

Before you consider ADMA Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADMA Biologics wasn't on the list.

While ADMA Biologics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

CPI News Breakdown: Key Market Moves to Follow
Understanding Oversold Stocks
Inside Pelosi’s Latest Stock Moves

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines